KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Aurora Cannabis (ACB) Research & Development (2017 - 2025)

Aurora Cannabis has reported Research & Development over the past 9 years, most recently at $934363.4 for Q4 2025.

  • Quarterly Research & Development rose 40.5% to $934363.4 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, up 3.16% year-over-year, with the annual reading at $2.6 million for FY2025, 3.36% down from the prior year.
  • Research & Development was $934363.4 for Q4 2025 at Aurora Cannabis, up from $656878.0 in the prior quarter.
  • Over five years, Research & Development peaked at $2.9 million in Q3 2021 and troughed at $547079.4 in Q1 2025.
  • The 5-year median for Research & Development is $718181.4 (2024), against an average of $1.2 million.
  • Year-over-year, Research & Development soared 50.39% in 2021 and then plummeted 69.24% in 2022.
  • A 5-year view of Research & Development shows it stood at $1.3 million in 2021, then tumbled by 45.48% to $702814.6 in 2022, then decreased by 18.27% to $574406.8 in 2023, then rose by 15.78% to $665023.9 in 2024, then surged by 40.5% to $934363.4 in 2025.
  • Per Business Quant, the three most recent readings for ACB's Research & Development are $934363.4 (Q4 2025), $656878.0 (Q3 2025), and $598299.7 (Q2 2025).